Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT05092451 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Lymphoma
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Multiple Myeloma
Plasma Cell Leukemia
Hodgkin Lymphoma
T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia
Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia
Blastic Transformation of Chronic Myeloid Leukemia
Germ Cell Tumors

Interventions

DRUG: Cyclophosphamide
DRUG: CAR.70/IL15-transduced CB-NK cells
DRUG: Fludarabine phosphate

Sponsor

M.D. Anderson Cancer Center